Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors
Description of Invention:
The invention relates to compositions of matter and methods for treating arthritis by modulating Tumor Necrosis Factor Alpha (TNF-alpha) signaling. TNF-alpha plays a key role in the pathogenesis of numerous diseases including rheumatoid and septic arthritis, and other autoimmune and inflammatory diseases. TNF-alpha mediates its effects through receptors that contain a Pre-ligand Assembly Domain (PLAD). The inventors have discovered compounds that interfere with PLAD can block the effects of TNF-alpha in vitro. Treatment of mice with these compounds in vivo ameliorated disease in several models of arthritis. Therefore, the compositions and methods of the current invention may lead to novel arthritis treatments.
Inventors:
Michael J. Lenardo et al. (NIAID)
Patent Status:
DHHS Reference No. E-095-2000/2 --
U.S. Provisional Application No. 60/694,015 filed 24 Jun 2005
Related Technologies: DHHS Reference No. E-095-2000/0 --
U.S. Patent Application No. 10/203,495 filed 09 Aug 2002, claiming priority to 11 Feb 2000, "Identification of a Novel Domain in the Tumor Necrosis Factor Receptor Ligand Family that Mediates Pre-Ligand Receptor Assembly and Function"
Licensing Status: In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
Portfolios: Cancer
Cancer -Therapeutics-Biological Response Modifiers-Cytokines Cancer -Therapeutics Cancer -Research Materials
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
